THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has received the FDA’s version of the minutes of the Type C meeting held on January 25, 2010. The minutes confirmed the Company’s interpretation of the points the Agency made during the meeting. In correspondence from the FDA prior to the meeting the Agency noted that they could not currently agree with the Company’s stated indication for the use of Androxal® in the treatment of secondary hypogonadism in men wishing to preserve fertility. Prior to the meeting the FDA requested a more rigorous definition of the intended patient population and data that would support the notion that exogenous testosterone had a negative impact on spermatogenesis. Of particular interest, in the written meeting minutes the FDA made the following comments:
